Report: Lilly must buy company or be acquired

Eli Lilly is set to lose the most revenue from its pharmaceuticals as a result of the patent cliff. Indeed, the drugmaker will say goodbye to more than 50 percent of its sales through 2020 as its brand name drugs lose their market exclusivity, according to estimates by Bernstein Research analyst Tim Anderson. And, as BNET's Jim Edwards notes this morning, the numbers suggest that Lilly must either acquire another company or be acquired. Story

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.